Mv Gentilini, M Doeyo, M Ortega, L Illidge Perez, C Rumbo, Pc Arriola Benitez, A Crivelli, M Rumbo, H Solar, Ge Gondolesi
Instituto de Medicina Traslacional, Trasplante y Bioingeniería (IMETTyB, CONICET, Universidad Favaloro), Laboratorio de Inmunología asociada al Trasplante, Buenos Aires, Argentina.
Fundación Favaloro Hospital Universitario, Unidad de Insuficiencia, Rehabilitación y Trasplante Intestinal, Buenos Aires, Argentina.
Therap Adv Gastroenterol. 2022 Nov 22;15:17562848221129787. doi: 10.1177/17562848221129787. eCollection 2022.
Pregnant patients with short bowel syndrome (SBS) and chronic intestinal failure (CIF) can successfully reach to term their pregnancies while on parenteral nutrition (PN) but with high rates of complications. The combination of rehabilitation surgery, combined with the use of novel treatment with enterohormones, especially semisynthetic glucagon-like peptide 2 (sGLP-2), has increased the chances to achieve intestinal sufficiency. Here, we report the case of a 33-year-old female with SBS/CIF (anatomy type 2), weaned off PN using sGLP-2 for 3.7 years, discontinued when she became pregnant. She was able to carry the pregnancy to term without any additional PN support. Considering that, we queried if the endogenous GLP-2 (eGLP-2) levels in this SBS patient, during the pregnancy and breastfeeding period, could be like those presented in healthy pregnant women and in non-pregnant SBS patients. Also, we inquired if there was any passage or increase in the plasmatic eGLP-2 from the fetus to the mother. Thus, we determined eGLP-2 levels in paired neonatal (cord blood) and maternal plasma samples from the SBS pregnant patient ( = 1), healthy pregnant women (controls, = 2), and non-pregnant SBS patients ( = 12). The results indicated that the SBS pregnant patient showed higher eGLP-2 levels than non-SBS pregnant patients and healthy pregnant women along all the period studied. Furthermore, we found that the maternal sample had higher eGLP-2 levels than the neonatal sample, suggesting that fetal contribution to maternal eGLP2 levels would be minor. In conclusion, this study not only reports for the first time a case of a patient with SBS that was able to achieve intestinal adaptation after combining the use of autologous reconstructive surgery and sGLP-2, but also enlightens the possibility of carrying out an uneventful pregnancy and lactation without any nutritional support and remaining independent of sGLP-2.
患有短肠综合征(SBS)和慢性肠衰竭(CIF)的孕妇在接受肠外营养(PN)时能够成功足月妊娠,但并发症发生率较高。康复手术与新型肠激素治疗(尤其是半合成胰高血糖素样肽2,即sGLP - 2)相结合,增加了实现肠道功能充足的机会。在此,我们报告一例33岁患有SBS/CIF(解剖学类型2)的女性病例,她使用sGLP - 2停用PN达3.7年,怀孕后停用。她能够在没有任何额外PN支持的情况下足月妊娠。考虑到这一点,我们探究了该SBS患者在妊娠和哺乳期的内源性GLP - 2(eGLP - 2)水平是否与健康孕妇及非妊娠SBS患者的水平相似。此外,我们还询问了胎儿血浆eGLP - 2是否会进入母体或导致母体血浆eGLP - 2升高。因此,我们测定了该SBS孕妇(n = 1)、健康孕妇(对照组,n = 2)和非妊娠SBS患者(n = 12)配对的新生儿(脐带血)和母体血浆样本中的eGLP - 2水平。结果表明,在整个研究期间,该SBS孕妇的eGLP - 2水平高于非SBS孕妇和健康孕妇。此外,我们发现母体样本中的eGLP - 2水平高于新生儿样本,这表明胎儿对母体eGLP - 2水平的贡献较小。总之,本研究不仅首次报告了一例通过自体重建手术和sGLP - 2联合使用实现肠道适应的SBS患者病例,还揭示了在无任何营养支持且不依赖sGLP - 2的情况下顺利妊娠和哺乳的可能性。